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Abstract
Background: There are currently no treatments for empathy deficits in neuropsychiatric disorders. Acute administration
of the hormone oxytocin has been associated with symptomatic improvements across animal models and several
neuropsychiatric disorders, but results of the majority of oxytocin randomised controlled trials (RCTs) of longer
duration have been negative or inconclusive. This lack of efficacy of may be due to rapid habituation to oxytocin
with chronic dosing. The objective of the present study is to describe the design of a phase 2 adaptive randomised
controlled crossover trial of intranasal oxytocin in frontotemporal dementia (FOXY) as an efficient model for
future investigations of symptomatic treatments in neuropsychiatric and neurodegenerative disorders.
Methods: Stage 1 will identify which of three dose schedules is most promising based on change in the
primary outcome measure, the Neuropsychiatric Inventory apathy/indifference domain score, over 6 weeks
of treatment. In stage 2, additional patients are enrolled at the most promising dose for preliminary efficacy
analysis when combined with stage 1 to determine if a phase 3 trial is warranted. Objective measures include facial
expression recognition, cerebrospinal fluid (CSF) oxytocin levels, and behavioural ratings of videotaped interactions.
Results: A total of 20 patients per arm will be entered into stage 1 for a total of 60 patients. In stage 2, an additional 40
patients will be enrolled in the most promising dose arm.
Conclusions: The use of adaptive, crossover designs and inclusion of objective measures of change in CSF oxytocin
levels and social behaviour will improve the efficiency and conclusiveness of RCTs of oxytocin and other symptomatic
treatments in neuropsychiatric disorders.
Trial registration: ClinicalTrials.gov, NCT03260920. Registered on August 24, 2017.
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Background
Social apathy and loss of empathy are hallmark features
of frontotemporal dementia (FTD), for which there are
currently no approved or effective treatments. Oxytocin,
a neuropeptide modulating social behaviour across species,
has been identified as a potential symptomatic therapy for
empathy and related social behaviour impairments across
neuropsychiatric conditions [1]. However, to date, the
evidence supporting the long-term use of oxytocin is
lacking. Identification of effective, evidence-based symp-
tomatic treatments for social cognition and behaviour
deficits in FTD and other neuropsychiatric disorders raises
several unique challenges for clinical trial design and im-
plementation. These challenges include symptom and be-
havioural heterogeneity, the nonlinear trajectory of many
behavioural symptoms over the course of the disease, lack
of harmonisation of assessment and outcome measures
across centres, and reliance on subjective caregiver reports
for key outcome measures [2–4]. Additional challenges
for randomised controlled trials (RCTs) of oxytocin include
potential differential responses according to sex, uncertain-
ties around brain penetration of intranasal formulations,
lack of dose-finding studies, and confirmation of target
engagement [5].
Further, specific to oxytocin, although numerous pub-
lished reports cite improvements in social cognition in
several disorders following single-dose administration
[6–8], longer-duration (2–6 weeks) RCTs of oxytocin
have had mixed results, with several showing no or small
effects [9–13]. These trials have used once- or twice-daily
dose schedules and have not included design elements to
address the potential habituation of responses with chronic
dosing that has been reported in non-human animal studies
[14–17]. In patients with FTD, short-term administration
of oxytocin was associated with improvement in caregiver
ratings of social behaviours and effects of emotional facial
expression recognition [18, 19], though longer-term studies
have not yet been conducted. A formal dose-finding study
in FTD identified 72 IU twice daily as the most feasible
dose, a dose larger than that used in the majority of oxyto-
cin RCTs in other disorders [19].
To address the lack of specific symptomatic treatment
in FTD and limitations of oxytocin and related trial designs
targeting social behaviours across a range of disorders to
date, we describe a novel adaptive proof-of-concept, phase
2, placebo-controlled, randomised crossover trial repurpos-
ing the hormone and neuropeptide oxytocin as a potential
symptomatic treatment for apathy/indifference and related
empathy deficits in patients with FTD. The objectives
of the study design are to (1) efficiently identify the most
promising dose schedule of oxytocin, given potential ha-
bituation to daily dosing, and (2) permit efficacy analysis of
the most promising dose compared with placebo to deter-
mine whether progression to a phase 3 trial is warranted.
We propose that this approach may inform the design and
conduct of other RCTs, particularly of symptomatic medi-
cations in FTD and related neuropsychiatric disorders.
Methods
Participants
Participants with a diagnosis of probable FTD (behavioural
variant FTD, FTD semantic subtype or FTD progressive
non-fluent aphasia) [20, 21] with current symptoms of
social apathy/indifference as measured by Neuropsychi-
atric Inventory (NPI) apathy/indifference severity sub-
scale score ≥ 2 [22], supportive brain imaging based on
centrally rated frontotemporal atrophy score of ≥ 2 based on
brain magnetic resonance imaging or computed tomography
[23] or FTD pattern of hypometabolism on fluorodeoxyglu-
cose positron emission tomography or hypoperfusion on
single-photon emission computed tomography, or known
causal genetic mutation, and a caregiver who sees the patient
daily for at least 3 h/d and who can administer all trial
medications are eligible for the study. Additional inclusion
criteria include a frontotemporal lobar degeneration Clin-
ical Dementia Rating (FTLD-CDR) [2] score consistent
with mild or moderate dementia, Mini Mental State
Examination score > 10/30, and stable baseline medica-
tions for ≥ 30 days. Exclusion criteria include recent
myocardial infarction, congestive heart failure, current
uncontrolled hypertension, bradycardia, long QTc or
hyponatremia. Participants will be enrolled at one of ten
FTD centres in the United States and Canada comprising
the Advancing Research & Treatment for Frontotemporal
Lobar Degeneration network (www.rarediseasesnetwork.
org/cms/artfl) plus three additional Canadian sites.
Study design
The study design features a placebo-controlled, rando-
mised crossover trial comparing changes in social apathy
and empathy following 6 weeks of oxytocin treatment
with 6 weeks of placebo, with a 6-week washout between
periods (Fig. 1). Although FTD is a progressive disorder,
changes in apathy over this interval are predicted to be
small; over an 8-week longitudinal study of patients with
FTD, the mean change in apathy ratings on the Frontal
Behavioral Inventory [24] was 0.13% (range − 6% to +7%)
[25]. In stage 1 the trial will compare three dosing
schedules of 72 IU intranasal oxytocin (daily, alternate
days, or every third day dosing) for patients with FTD
compared with placebo. At the end of stage 1, a Bayesian
analysis will be conducted to identify the most promis-
ing dose schedule, termed the ‘target’ dose schedule. In
stage 2, forty additional patients will be enrolled at the
target dose schedule. In both stages the primary out-
come measure is mean change from baseline on the
Neuropsychiatric Inventory (NPI) apathy/indifference
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domain score comparing on-active versus on-placebo.
At the end of stage 2, data from patients receiving the
target dose (from stage 1 and stage 2) are combined in
the efficacy analysis. An optional substudy measuring
cerebrospinal fluid (CSF) oxytocin levels at the end of
the oxytocin and placebo treatment periods will con-
firm CSF oxytocin level rises in FTD and determine
whether changes in CSF oxytocin levels correlate with
behavioural measures. The three dosing schedules in
the proposed study were selected on the basis of (1) a
prior dose-finding study of intranasal oxytocin in FTD
identifying 72 IU as the most promising feasible dose
[19], (2) estimated half-life of oxytocin in the central
nervous system (CNS) [26–28], and (3) predictions that
dosing < 2 d/wk would be unlikely to result in a clinic-
ally meaningful effect.
Randomisation
Randomisation for stages 1 and 2 will be stratified
across the treatment groups listed above according to
sex and disease severity (mild vs. moderate) because
oxytocin is known to have differential behavioural ef-
fects based on sex [29], and pilot data suggest that ef-
ficacy may differ as a function of disease severity and
the integrity of remaining oxytocin receptor-positive
neurons [19, 30]. The FTLD-CDR allows severity as-
sessment and stratification across the different FTD
phenotypes included in the trial. The number of cen-
tres required for the trial precludes stratification ac-
cording to centre. Participants will be randomised
using variable block sizes concealed from participating
sites.
Outcome measures and minimum clinically significant
difference
The NPI apathy/indifference domain score is the desig-
nated primary outcome, with a ≥ 2-point improvement on
the NPI identified to be clinically significant and to repre-
sent meaningful improvement in patient symptoms of ap-
athy and loss of empathy. A 2-point minimal clinically
important difference is consistent with prior trials using
the NPI in FTD [31, 32]. In the pilot study of oxytocin in
Fig. 1 Two-stage phase II adaptive crossover trial design for intranasal oxytocin for frontotemporal dementia (FOXY). In stage 1, a total of 60
patients with frontotemporal dementia (FTD) are randomized to one of three dose schedules. In the crossover design, baseline assessments are
completed at the beginning of each treatment period. After baseline, participants receive twice-daily intranasal sprays of placebo or oxytocin for
6 weeks and then undergo complete outcome assessments and optional lumbar puncture. The first treatment period is followed by a washout
period with no sprays given for 6 weeks. At the end of the washout period, participants are re-baselined prior to 6 weeks of twice-daily intranasal
spays of the alternate drug (placebo or oxytocin). In stage 2, 20 additional patients with FTD are randomized to the most promising dose
identified at the planned interim analyses at the end of stage 1, and complete procedures identical to those in stage 1 are performed
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FTD, a 2-point improvement corresponded to a reduction
of approximately 30% in apathy/indifference ratings. The
NPI apathy domain score was selected as the primary out-
come measure because it was where we saw the most sig-
nificant differences in our pilot study [19]. In the pilot
study no significant differences were observed on the Ap-
athy Evaluation Scale, which we attributed to the lack of
items indexing increased conversations or empathic be-
haviours towards family members, and several items re-
lated to insight, which is impaired in FTD and not
expected to be remedied by oxytocin. Compared with
other available measures, the NPI prompts for the caregiver
are holistic enough to capture both social and non-social
apathy and interactions with others that we hypothesised
may be modulated by oxytocin, as well as to capture both
the severity and frequency of such behaviours within the
domain score. Secondary outcome measures included
change in the Interpersonal Reactivity Index empathic con-
cern score [33], NPI caregiver distress scores [22], and the
Revised Self-Monitoring Scale [34]. Accuracy of emotional
facial expression recognition and blinded ratings of natural-
istic videotaped behaviours of patients as they have a meal
with their caregivers using the Social Observation
Checklist [35] will serve as a measure of pharmacody-
namic effects (Table 1). Difference in CSF levels of oxy-
tocin following the oxytocin vs. placebo treatment
period will be examined to confirm entry of intranasally
administered oxytocin into the CSF. Potential adverse
symptoms will be monitored, and changes in serum
sodium level, heart rate, QTc and blood pressure will
be assessed at baseline and the beginning and end of
each treatment period. Compliance with treatment will
be monitored with daily caregiver-completed adminis-
tration logs and measurement of residual volumes.
Data analysis and pre-specification of adaptive design
decision algorithms
Stage 1
At the completion of stage 1 the analysis described
below will take place to select the most promising
dose schedule that will show the largest estimated
mean change (benefit) of oxytocin relative to placebo
on the primary outcome measure, the NPI apathy/in-
difference domain scale scores. A linear model with
covariates for sex and order of treatment in the cross-
over will be used to estimate the efficacy of each treat-
ment arm. Each patient will have a 6-week
post-treatment change from baseline score for each
treatment phase (i.e., week 6 − week 0 vs. week 18 −
week 12). The within-patient difference in these values
‘on active’ vs. ‘on placebo’, Y, will be modelled assum-
ing a normal linear model: Y~N(θt + β1X1 + β2X2, σ
2),
where X1 is an indicator of the patient having the ac-
tive as the first treatment in the crossover and X2 an
indicator of the patient being a male. The efficacy of
the three active treatment arms are captured by the
mean change in total NPI apathy/indifference treat-
ment parameters, θ1, θ2, and θ3.
The treatment arm with the largest estimated mean
change (benefit) will be selected for stage 2. Note that
the dosing strategy selection analysis does not depend
on a formal hypothesis test. If two or more dose sched-
ules appear equally promising (i.e., similar estimated
mean change), consideration of side effect profile can be
used to select the most promising and tolerable dose
schedule. If two or more dose schedules appear equally
promising and their side effect profiles are similar, the
more frequent dose schedule will be selected in stage 2.
Enrolment in the groups and subgroups is relatively
small, and important information may be gained by CSF
oxytocin measurements as well as secondary outcome
measures to inform future studies, thus no futility ana-
lysis will be conducted at the end of stage 1.
Stage 2
Given the crossover design and proof-of-concept nature
of the study, a variant of a per-protocol analysis will be
conducted on the patients completing the protocol, de-
fined as those who entered into both phases of the
treatment, have a primary outcome measure, and took
≥ 70% of sprays. A modified intention-to-treat analysis
will be conducted as a supportive analysis, including all
patients who were randomised and received at least
one dose of study drug. Because the primary outcome
measure can be obtained via telephone interview with
the caregiver, wherever available, this will be collected
for patients who do not complete the study, with the
last observation carried forward.
Table 1 Outcome assessments completed at baseline
assessment, end of treatment period 1, after washout (baseline
2), and end of treatment period 2
Primary outcome measure:
• Neuropsychiatry Inventory (NPI) apathy/indifference domain score [42]
Secondary outcome measures:
• Interpersonal Reactivity Index (IRI) empathic concern scale and total
score [33]
• Clinician’s Global Impression of Change (apathy) (m-CGIC) scores [43, 44]
• Emotional facial expression recognition performance [17]
• Revised Self-Monitoring Scale (RSMS) score [45]
• NPI caregiver distress scores on NPI apathy/indifference scale and total
caregiver distress scores [42]
• Total NPI scores
• Cambridge Behavioural Inventory [46]
• Addenbrooke’s Cognitive Examination III [47]
• Social Observation Checklist blinded central ratings of videotaped
meals with patients and caregivers [35].
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Results
Sample size justification
Primary outcome measure
Sample size and clinical trial simulations were based on
a published pilot study of oxytocin in FTD and desig-
nated minimal clinically significant difference of 2 points
on the NPI apathy/indifference score [19]. Simulations
were conducting using the Fixed and Adaptive Clinical
Trial Simulator (www.berryconsultants.com) and varying
the number of patients and effect sizes in stage 1 to show
the operating characteristics. The simulations assumed an
SD of 3.3 between the placebo and active arms (based on
prior published studies of mean differences and SD on the
NPI for an individual patient) [18]. Differences from 0 to 3
in the effect of an arm relative to placebo were explored
for each trial design. For each design scenario 10,000 sim-
ulated trials were conducted. These simulations demon-
strate that for a mean difference of 2 points or more from
placebo, a sample size of 54 patients receiving the target
dose schedule has an 86% probability of showing superior-
ity to placebo at the end of stage 2 (Additional file 1). To
enrol at least 54 patients in the target dose schedule, a
total of 100 patients will be enrolled in this trial. In stage
1, 20 patients with FTD will be randomised to each of the
three arms (daily, alternate days, or third-day dosing).
In stage 2, an additional 40 patients will be randomised
to the target dose schedule, resulting in a sample size
of 60 patients at the target dose schedule across both
study phases. With enrolment of 60 patients (30 males
and 30 females) in the target dose schedule, subgroup
analysis based on sex will have a power of 80% to detect
a 2-point difference on the NPI apathy domain based
on within-patient SD of differences of 3.3 in our pilot
study [19] and will permit up to 15% loss of data due to
potential non-compliance or loss to follow-up. For the
main secondary outcome measure of interest, the em-
pathic concern scale of the IRI, based on an SD of the
change from baseline of 1.75 [19], a sample of 20 pa-
tients per arm per sex provides power of 80% to detect
a 1-point difference.
CSF substudy
Following a study of a single dose of 24 IU intranasal
oxytocin in which researchers found statistically signifi-
cant increases in the adult volunteers’ CSF oxytocin
measured at 75 min (+ 64%) [26], using paired t tests, a
sample of 10 participants from the daily oxytocin dose
schedule group provides power > 0.95 to detect a signifi-
cant difference in CSF oxytocin levels after 6 weeks of
oxytocin vs. placebo treatment.
Discussion
The proposed trial represents an application of an adap-
tive crossover Bayesian design to improve the efficiency of
determining the efficacy of symptomatic treatment for
FTD. Specifically, and building on the Co-Enzyme Q10 in
Amyotrophic Lateral Sclerosis study [36], the two-stage
design permits dose schedule selection and efficacy assess-
ment with a smaller sample size than traditional designs.
The design addresses potential limitations of prior RCTs
evaluating the effects of oxytocin on behaviour in other
neuropsychiatric disorders by use of a crossover design,
inclusion of an objective rating of videotaped naturalistic
behaviours during each treatment phase, and measure-
ments of CSF oxytocin levels to confirm entry of drug into
the CNS. Inclusion of symptom-specific and global
measures of caregiver distress will enable identification
of meaningful clinical change for each measure for the
present study as well as future interventional studies.
Bayesian adaptive designs are increasingly employed in
state-of-the-art clinical trials [36, 37] and are endorsed
by the U.S. Food and Drug Administration (FDA) and
Patient-Centered Outcomes Research Institute. Adaptive
designs are particularly helpful when there are multiple
goals in the trial, such as finding the best dose schedule and
confirming its efficacy. Extensive trial simulations have
been used to compare different adaptations and parameters
to select the most effective and efficient design. Advantages
of this Bayesian adaptive design include smaller sample size
to determine which treatment is the most effective, a re-
duced delay in identification of ineffective treatments, and
decreasing the time to trial conclusions with the seamless
shift between study phases/goals (i.e., dose schedule finding
to efficacy). These are efficiencies commonly seen in adap-
tive trials [38]. Compared with traditional clinical trial
designs, use of an adaptive design for the present study
results in a 20% reduction in the number of patients needed
(Table 2).
Table 2 Efficiencies in sample size of adaptive crossover trial
compared with traditional and parallel trial designs
Study design Sample size
dose selectiona
Sample size
POC efficacy
Total sample
size
Power
Traditional parallel
armb
62 44 106 0.86
Traditional
crossover
54 44 106 0.86
Adaptive crossover 60 24 84 0.86
aPower calculations performed using G*Power were based on an effect size
from a minimum clinically significant difference of 2 points on the NPI apathy/
indifference domain score (d = 0.7) and power of 0.80 to permit analysis for
males and females, with effect size of 0.7 based on pilot study results of a 3-
point difference (dkarr = 0.7) [11]. For comparison, sample sizes assuming a
smaller effect size are shown for each design
bTraditional trial design-based on factor design (analysis of covariance). Four
groups (three dose schedules + placebo), df = 3, disease severity as covariate,
with sample size doubled to permit separate analysis of males and females
Traditional crossover design comprised three groups, df = 2, disease severity as
covariate, with sample size doubled to permit separate analysis of males
and females
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Recent RCTs of intranasal oxytocin for social cognition
deficits in autistic spectrum disorders have had mixed
results [3, 10]. Indications that caregiver assessments of
change in behaviour are strongly correlated with assump-
tions about treatment status [3] have led the National
Institute of Mental Health to specify that objective mea-
sures of treatment response should be included in studies
of oxytocin in patient populations [39]. Given the lack of
insight in patients with FTD and reliance on caregiver
judgments regarding behavioural change, the same po-
tential confound exists for behavioural outcome mea-
sures in FTD. Recent development and validation of
the Social Observation Checklist using videotaped en-
counters between patients and caregivers during meals
[35] provides an objective means by which to quantify
naturalistic behaviours and reduce site-related variability by
use of a blinded central rater. Use of a crossover design is
also important in disorders such as FTD, where caregiver
measurements are an important outcome measure and
when significant subject-to-subject symptom heterogeneity
is present. For example, all patients enrolled will meet
inclusion criteria for social apathy and empathy deficits, the
main behavioural symptoms potentially impacted by oxyto-
cin, but patients are expected to have different combina-
tions of other FTD behavioural symptoms (i.e., impulsivity,
obsessive-compulsive behaviours, aggression) which could
differentially interact with the effects of interest. The cross-
over allows the analysis to account for the subject-to-sub-
ject heterogeneity explicitly, greatly reducing the SD across
subjects. Inclusion of oxytocin CSF measurements will pro-
vide needed data to determine whether CSF level changes
correlate with behavioural changes, and thus inform
dosing strategies. In the event that the clinical out-
comes are positive, these data may help to refine dose
selection for a phase 3 trial. In the event that there is
no efficacy signal, the data would confirm that suffi-
cient drug reached the CNS and therefore would sup-
port a negative (as opposed to inconclusive) result for
oxytocin.
Limitations
Currently, a direct measure of oxytocin target engagement
in humans is limited by the lack of an available positron
emission tomography tracer. Although the CSF measure-
ments should aid in distinction between a negative trial
and an inconclusive trial due to lack of drug in the CNS, it
is possible that oxytocin levels may rise in specific brain
regions proximal to the site of administration (basal
forebrain, ventral frontal and mesial temporal lobes) or
secondary to trigger of endogenous oxytocin release with-
out significant rises in CSF [40]. However, if CSF oxytocin
levels do not show measurement increases and the object-
ive performance measures do not show efficacy, this would
indicate that a phase 3 trial in FTD is not warranted. The
present study will also address whether a 2-point improve-
ment on the NPI, which has been used in prior clinical
trials [31, 41], reflects a clinically significant reduction in
caregiver distress. These critical indicators of the value of
potential treatments for FTD will be assessed with the NPI
caregiver distress scores. If results of this RCT are positive,
knowledge of how a change in NPI scores corresponds to
caregiver distress scores will critically inform designation of
a minimal clinically significant difference for a phase 3 trial
and FTD more globally.
Conclusions
Adaptive design and crossover trials are uncommon de-
signs in clinical trials in dementia. Building on the use
of adaptive trial designs to assess potential neuropro-
tective treatments in neurodegenerative disorders [36],
we describe an application of an adaptive crossover design
to facilitate dose selection and efficacy assessment for
symptomatic treatment in FTD. The design and inclusion
of objective measures to index outcomes related to behav-
iour and emotion can be applied to study of oxytocin and
other symptom-focused treatments in other neuropsychi-
atric and neurodegenerative disorders.
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